378 related articles for article (PubMed ID: 33256492)
1. Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units.
Naji-Talakar S; Sharma S; Martin LA; Barnhart D; Prasad B
Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):273-289. PubMed ID: 33256492
[No Abstract] [Full Text] [Related]
2. Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters.
Cheung KWK; van Groen BD; Burckart GJ; Zhang L; de Wildt SN; Huang SM
J Clin Pharmacol; 2019 Sep; 59 Suppl 1(Suppl 1):S56-S69. PubMed ID: 31502692
[TBL] [Abstract][Full Text] [Related]
3. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
[TBL] [Abstract][Full Text] [Related]
4. Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics.
Elmorsi Y; Barber J; Rostami-Hodjegan A
Drug Metab Dispos; 2016 Jul; 44(7):992-8. PubMed ID: 26712821
[TBL] [Abstract][Full Text] [Related]
5. A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation.
Ladumor MK; Thakur A; Sharma S; Rachapally A; Mishra S; Bobe P; Rao VK; Pammi P; Kangne H; Levi D; Balhara A; Ghandikota S; Joshi A; Nautiyal V; Prasad B; Singh S
Sci Rep; 2019 Jul; 9(1):9709. PubMed ID: 31273226
[TBL] [Abstract][Full Text] [Related]
6. Ontogeny of Drug-Metabolizing Enzymes.
Thakur A; Parvez MM; Leeder JS; Prasad B
Methods Mol Biol; 2021; 2342():551-593. PubMed ID: 34272706
[TBL] [Abstract][Full Text] [Related]
7. Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States.
Sharma S; Suresh Ahire D; Prasad B
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S17-S35. PubMed ID: 33205430
[TBL] [Abstract][Full Text] [Related]
8. Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species.
van Groen BD; Nicolaï J; Kuik AC; Van Cruchten S; van Peer E; Smits A; Schmidt S; de Wildt SN; Allegaert K; De Schaepdrijver L; Annaert P; Badée J
Pharmacol Rev; 2021 Apr; 73(2):597-678. PubMed ID: 33608409
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
[TBL] [Abstract][Full Text] [Related]
10. The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study.
Cristea S; Krekels EHJ; Rostami-Hodjegan A; Allegaert K; Knibbe CAJ
AAPS J; 2020 Jun; 22(4):87. PubMed ID: 32566984
[TBL] [Abstract][Full Text] [Related]
11. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Johnson TN; Rostami-Hodjegan A
Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
[TBL] [Abstract][Full Text] [Related]
12. Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.
Rodieux F; Gotta V; Pfister M; van den Anker JN
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S173-92. PubMed ID: 27385174
[TBL] [Abstract][Full Text] [Related]
13. Commentary: A Myriad Aberrations on Information of Ontogeny of Drug Metabolizing Enzymes in the Pediatric Population: An Obstacle for Personalizing Drug Therapy in the Pediatric Population.
Uppugunduri CR; Ansari M
Drug Metab Lett; 2016; 10(2):72-4. PubMed ID: 26908134
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Clearance in Neonates and Infants (≤ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.
Mahmood I; Ahmad T; Mansoor N; Sharib SM
J Clin Pharmacol; 2017 Apr; 57(4):476-483. PubMed ID: 27704554
[TBL] [Abstract][Full Text] [Related]
15. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Clin Pharmacol Ther; 2021 Jun; 109(6):1618-1630. PubMed ID: 33283268
[TBL] [Abstract][Full Text] [Related]
16. Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics.
Miyagi SJ; Long-Boyle JR
Drug Metab Lett; 2015; 9(2):80-7. PubMed ID: 26031462
[TBL] [Abstract][Full Text] [Related]
17. Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group.
Brouwer KL; Aleksunes LM; Brandys B; Giacoia GP; Knipp G; Lukacova V; Meibohm B; Nigam SK; Rieder M; de Wildt SN;
Clin Pharmacol Ther; 2015 Sep; 98(3):266-87. PubMed ID: 26088472
[TBL] [Abstract][Full Text] [Related]
18. Ontogeny of Small Intestinal Drug Transporters and Metabolizing Enzymes Based on Targeted Quantitative Proteomics.
Kiss M; Mbasu R; Nicolaï J; Barnouin K; Kotian A; Mooij MG; Kist N; Wijnen RMH; Ungell AL; Cutler P; Russel FGM; de Wildt SN
Drug Metab Dispos; 2021 Dec; 49(12):1038-1046. PubMed ID: 34548392
[TBL] [Abstract][Full Text] [Related]
19. Challenges and Opportunities for Increasing the Knowledge Base Related to Drug Biotransformation and Pharmacokinetics during Growth and Development.
Leeder JS; Meibohm B
Drug Metab Dispos; 2016 Jul; 44(7):916-23. PubMed ID: 27302933
[TBL] [Abstract][Full Text] [Related]
20. Ontogeny of Phase I Metabolism of Drugs.
Allegaert K; van den Anker J
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S33-S41. PubMed ID: 31502685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
